-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Metastasis is the main cause of cancer-related deaths.
Compared with the control (left), C26 therapy (right) reduced the number of lung metastatic tumors in mice injected with HSNCC cells
Image source: 2021 Khalil et al.
Many cancer patients will have disease recurrence, which often forms new tumors at the same site in the body or metastases to other parts of the body a few years or decades after the initial treatment; these secondary tumors are usually treated Tolerance and produced by a single tumor cell, it tends to stay in a dormant state for a long time before it is reactivated and starts to proliferate.
In previous studies, researchers found that the ability of cancer cells to stay dormant may be controlled by a protein called NR2F1.
Researcher Aguirre-Ghiso explained that, therefore, we believe that using a small molecule to activate NR2F1 may be a very attractive clinical strategy to induce cancer cells to enter a dormant state and prevent cancer recurrence and metastasis
The researchers then tested whether C26 can prevent the metastasis of cancer in mice.
Researcher Sosa pointed out that drugs that activate NR2F1 may be particularly effective in the treatment of breast cancer.
Note: The original text has been deleted
Original source:
Bassem D.
